Abstract

Systemic and intrapleural chemotherapy for metastatic tumor pleurisy was carried out in cats with breast carcinoma. The animals (n=18) were divided into 2 groups. Cats of the systemic chemotherapy group received 3-6 courses of taxotere (30 mg/m(2); n=7) or 3 courses of taxotere (20 mg/m(2)) in combination with doxorubicin (20 mg/m(2)at 21-day intervals (n=5) during the adjuvant period of therapy for metastatic tumor pleurisy. Objective effect was attained in 10 (84.6%) cats: partial remission in 3 (25%) and complete remission in 7 (58.3%, p>0.05) cats. Metastatic pleurisy progressed in 2 (16.7%) cats. The median time to progression reached 1.79 months, median lifespan 2.8 months. The animals of intrapleural chemotherapy group (n=6) received 1-4 courses of cyclophosphamide (250 mg/m(2)) at 1-week interval during the adjuvant period without therapy for malignant pleurisy. Malignant pleurisy progressed in all cats. The median time to progression was equal to median lifespan (0.6 months). The therapy for malignant pleurisy in cats with breast cancer is regarded as the second-line chemotherapy with taxotere preferable as a monotherapy or in combination with doxorubicin.

Links

Aggregator Full Text

Authors

Yakunina MN, Treshalina EM

Institution

N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia. irsovet@yandex.ru

Source

Bulletin of experimental biology and medicine 150:5 2011 Mar pg 642-4

MeSH

Animals
Antineoplastic Combined Chemotherapy Protocols
Cats
Disease Progression
Doxorubicin
Drug Administration Schedule
Female
Mammary Neoplasms, Experimental
Neoplasm Metastasis
Pleura
Pleurisy
Taxoids
Treatment Outcome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22235405